JARID2 and EZH2, the eminent epigenetic drivers in human cancer

Gene. 2023 Aug 30:879:147584. doi: 10.1016/j.gene.2023.147584. Epub 2023 Jun 21.


Cancer has become a prominent cause of death, accounting for approximately 10 million deaths worldwide as per the World Health Organization report 2020. Epigenetics deal with the alterations of heritable phenotypes, except for DNA alterations. Currently, we are trying to comprehend the role of utmost significant epigenetic genes involved in the burgeoning of human cancer. A sundry of studies have reported the Enhancer of Zeste Homologue2 (EZH2) as a prime catalytic subunit of Polycomb Repressive Complex2, which is involved in several pivotal activities, including embryogenesis. In addition, EZH2 has detrimental effects leading to the onset and metastasis of several cancers. Jumonji AT Rich Interacting Domain2 (JARID2), an undebated crucial nuclear factor, has strong coordination with the PRC2 family. In this review, we discuss various epigenetic entities, primarily focusing on the possible role and mechanism of EZH2 and the significant contribution of JARID2 in human cancers.

Keywords: Cancer; EZH2; Epigenetics; JARID2; Polycomb repressive complex.

Publication types

  • Review

MeSH terms

  • Enhancer of Zeste Homolog 2 Protein / genetics
  • Epigenesis, Genetic
  • Humans
  • Neoplasms* / genetics
  • Polycomb Repressive Complex 2* / genetics
  • Polycomb Repressive Complex 2* / metabolism
  • Polycomb-Group Proteins / genetics


  • Polycomb Repressive Complex 2
  • Enhancer of Zeste Homolog 2 Protein
  • Polycomb-Group Proteins
  • EZH2 protein, human
  • JARID2 protein, human